Moderna News - September 2026
🟢 Moderna is trading 4.72% up today after Phase 3 trial met recurrence-free-survival endpoint
Moderna is trading 4.72% up at $190.70 after positive Phase 3 INTerpath-001 results for intismeran autogene with Merck’s Keytruda. - The trial met its...
🟢 Moderna is trading 5% up today after positive Phase 3 melanoma results
Moderna is trading 5% up at $181.61 after Moderna and Merck announced positive Phase 3 melanoma results. - The rally extends Moderna’s 12.27% gain on...
Moderna Lands the Biggest Stage in Cancer Medicine — But Can a Conference Slot Justify a $7 Billion Single-Day Gain?
Shares of Moderna surged 10.8% to $170.63 Monday after the company announced its personalized mRNA melanoma vaccine data secured a coveted Presidential...
🟢 Moderna is trading 10.77% up today after melanoma-vaccine data secured Presidential Symposium placement
Moderna is trading $170.63 (+10.77%) after announcing on September 21, 2026, that Phase 3 melanoma-vaccine data for intismeran autogene will receive a...
🟢 Moderna is trading 10% up today as markets recover after September 16 rate hike
Moderna is trading at $160.30, up +10.08%, as U.S. markets recover after the Federal Reserve’s September 16 rate hike, which removed immediate policy...
🟢 Moderna is trading 10% up today after GSK advances mRNA flu vaccine
Moderna is trading at $154.38, up +10.01%, after GSK’s decision to advance an mRNA flu vaccine into Phase III was interpreted as validation of Moderna’s...